Open AccessAcute Sildenafil Use Reduces 24‐Hour Blood Pressure Levels in Patients With Resistant Hypertension: A Placebo‐Controlled, Crossover Trial
Author(s) -
Santa Catharina Arthur,
Modolo Rodrigo,
Ritter Alessandra Mileni Versuti,
Quinaglia Thiago,
Amorim Rivadávio Fernandes Batista,
Moreno Heitor,
Faria Ana Paula
Publication year - 2016
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/jch.12850
Subject(s) - medicine , sildenafil , placebo , crossover study , ambulatory blood pressure , blood pressure , anesthesia , ambulatory , hemodynamics , cardiology , diastole , alternative medicine , pathology
The authors previously demonstrated that acute administration of sildenafil—a phosphodiesterase 5 (PDE5) inhibitor—improves hemodynamic parameters in patients with resistant hypertensive (RH), but its effect on ambulatory blood pressure monitoring (ABPM) is unknown. This interventional, nonrandomized, single‐blinded, placebo‐controlled, crossover trial included 26 patients with RH. A dose of sildenafil (187.5mg) was given, and after a washout period of 14 days the patients received a single oral dose of placebo and the protocol was repeated. The patients underwent 24‐hour ABPM recordings the day before and immediately after the protocols. The reduction of systolic (−8.8±1.4 vs 1.3±1.2 mm Hg, P =.02), diastolic (−5.3±3.3 vs 1.8±1.1 mm Hg, P =.03), and mean (−7.9±3.6 vs 0.8±0.9 mm Hg, P =.01) 24‐hour BP were found after the use of sildenafil compared with placebo. Improvement in daytime BP levels was also observed (systolic −6.0±4.7 vs 4.4±1.5 mm Hg [ P =.02] and mean −4.8±3.9 vs 3.5±1.4 mm Hg [ P =.02] for sildenafil vs placebo, respectively). Considering its antihypertensive effect, sildenafil may represent a therapeutic option for RH treatment.